Product Highlight - Evusheld

Active ingredient: Tixagevimab, cilgavimab

Indication: Treatment of mild to moderate COVID-19 & pre-exposure prophylaxis of COVID-19 in adults & adolescents ≥12 yr weighing at least 40 kg.

Dosage & Administration: IM May be given as soon as possible after a +ve viral test for SARS-CoV-2 & w/in 7 days after onset of symptoms.
Administered as 2 separate sequential IM inj at different inj sites, preferably 1 in each of gluteal muscles. Adult & adolescents ≥12 yr, weighing at least 40 kg Treatment of mild to moderate COVID-19 Recommended dose: 600 mg (300 mg tixagevimab & 300 mg cilgavimab). Prophylaxis 300 mg (150 mg tixagevimab & 150 mg cilgavimab).

TH-13081 EXP 10/02/2025